Artery Elasticity After Switch From Epzicom to Truvada
Status:
Terminated
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
Recent research as suggested that use of the HIV medication abacavir (Ziagen, or
co-formulated with lamivudine as Epzicom) may increase risk for heart disease, though
findings from multiple studies have been inconsistent. This pilot study will examine vascular
function, a marker of heart disease risk, among patients taking abacavir as part of their HIV
medications and are then randomized to: 1) switch to tenofovir, another HIV medication, or 2)
continue to take abacavir.
Phase:
Phase 4
Details
Lead Sponsor:
Hennepin Healthcare Research Institute Minneapolis Medical Research Foundation
Treatments:
Abacavir Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Tenofovir